Anuh Pharma advances after completion of USFDA inspection

USFDA has successfully completed an inspection at Anuh Pharma’s facility. Reacting to this news, the shares of the company climbed nearly 14 per cent intraday on Friday.

The facility was inspected by the US Food and Drug Administration (USFDA) from September 16, 2019 to September 20, 2019. At the end of the inspection, no observation (483) was issued.

Last month, the pharma company had received approval from WHO - Geneva Prequalification that the Prequalification Inspection Group has recommended that the API's Pyrimethamine, Pyrazinamide and Sulfadoxine can be considered to be compliant with the standards of Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (APIs) published by the World Health Organisation (WHO) for manufacturing and packaging of APIs by chemical synthesis.

Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.

The shares of Anuh Pharma on Friday opened at Rs. 142 against Thursday’s close of Rs. 137.90. At 15:00 hours it was trading at Rs. 150.35, gaining 9.03 per cent from its previous close. The stock hit an intraday high of Rs. 157.40 and intraday low was Rs. 138.05. Its 52-week high was Rs. 173 and 52-week low was Rs. 101.25 per share on the BSE.